Fig. 1 · Structure
Documents & Downloads
BF844
Mitigate Hearing Loss
BF844 is a small molecule designed to target the CLRN1 (clarin-1) N48K mutation associated with Usher Syndrome Type III. It functions by promoting the transport of the mutant CLRN1 protein to the plasma membrane, thereby aiding in cellular function. BF844 has demonstrated significant efficacy in preserving hearing in in vivo models, making it a valuable tool for research into therapeutic strategies for hearing loss linked to genetic mutations.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1404506-35-9 |
| Applications | Mitigate Hearing Loss |
| Formula | C21H19ClN4O |
| Molecular Weight | 378.85 |
| SMILES | CC(O)(C)CN1N=C(C2=CC=CC=C2)C3=C(Cl)C(C4=CC=CC=C4)=NN=C31 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.